Market capitalization | $8.73m |
Enterprise Value | $-810.00k |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.05 |
EV/Sales (TTM) EV/Sales | -4.05 |
P/S ratio (TTM) P/S ratio | 43.65 |
P/B ratio (TTM) P/B ratio | 1.16 |
Sales growth (TTM) Sales growth | 38.08% |
Turnover (TTM) Turnover | $200.00k |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
2 Analysts have issued a Inhibikase Therapeutics Inc forecast:
2 Analysts have issued a Inhibikase Therapeutics Inc forecast:
Mar '24 |
+/-
%
|
||
Turnover | 0.20 0.20 |
43%
43%
|
|
Gross income | 0.02 0.02 |
-
|
|
EBITDA | -20 -20 |
10%
10%
|
EBIT (operating result) EBIT | -20 -20 |
11%
11%
|
Net profit | -19 -19 |
7%
7%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP™ Drug Innovation Engine technology. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.
Head office | United States |
CEO | Milton Werner |
Employees | 8 |
Founded | 2008 |
Website | www.inhibikase.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.